Physician profile
Vicky Bhagat
NPI 1316387475
$4,116.07
in general payments reported to CMS, 2019-2025
21 companies · $538 in 2025
The $538 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $121 · 2021: $342 · 2022: $785 · 2023: $221 · 2024: $613 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,717.94 | 2019-2024 | |
| Abbvie INC. | $526.78 | 2019-2025 | |
| Endogastric Solutions, INC | $329.07 | 2019-2023 | Esophyx |
| Madrigal Pharmaceuticals | $188.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $170.77 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $164.46 | 2022-2025 | |
| Conmed Corporation | $136.23 | 2023 | Conmed Hemostasis, Conmed Biliary, Conmed Generators |
| Medtronic, INC. | $124.58 | 2025 | Nexpowder |
| E.R. Squibb & Sons, L.L.C. | $123.18 | 2022 | |
| Genzyme Corporation | $117.27 | 2024 | |
| Janssen Scientific Affairs, LLC | $108.14 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.51 | 2019-2024 | Xifaxan |
| Olympus America INC. | $55.36 | 2019 | |
| Concordia Pharmaceuticals INC. | $54.50 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.74 | 2023-2024 | Entyvio |
| Janssen Biotech, INC. | $30.61 | 2020-2024 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $26.02 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $16.16 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $14.37 | 2024 | |
| Lilly USA, LLC | $13.25 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Bhagat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.